Guangzhou and London – May 22, 2025 – Bio-Thera Solutions,Ltd (688177:SH), a commercial-stage biopharmaceutical company developing apipeline of biosimilars and innovative assets and Hikma Pharmaceuticals PLC,along with its wholly owned subsidiary Hikma Pharmaceuticals USA Inc. today announcedtha...
DetailsGuangzhou, China --(BUSINESSWIRE)-- Bio-TheraSolutions, Ltd. (SH: 688177), a commercial-stage pharmaceutical company, todayannounced that dosing has begun in Phase I clinical study to compare thepharmacokinetics and safety of BAT6026, an agonist monoclonal antibodytargeting OX40 in cancer patient vo...
Guangzhou, China --(BUSINESSWIRE)-- Bio-TheraSolutions, Ltd. (SH: 688177), a commercial-stage pharmaceutical company, todayannounced that dosing has begun in Phase I clinical study to compare thepharmacokinetics and safety of BAT6005, a monoclonal antibody targeting TIGITin cancer patient volunteers...
GUANGZHOU,China and MOSCOW, Russia ---(Businesswire)--- Bio-Thera Solutions, Ltd. (688177:SH), a commercial-stage biopharmaceuticalcompany developing a pipeline of innovative therapies and a pipeline ofbiosimilars, today announced the company has reached licensing and supply agreements with Pharmapa...
